Dr JLN Sastry, Ayurveda Consultant and Practitioner, and former CEO of the National Medicinal Plants Board (NMPB) under the Ministry of AYUSH, examines the growing debate around Ashwagandha regulation and its implications for India’s Ayurveda and nutraceutical industries. He argues that policymaking must remain science-driven, product-specific, and balanced to protect both consumer safety and India’s global leadership in herbal wellness.
Ashwagandha (Withania somnifera) is one of India’s most valued botanicals, with deep roots in Ayurveda and growing relevance in the global nutraceutical market. For centuries, it has been associated with rejuvenation, resilience, and overall wellness. Today, as consumer interest in natural health solutions continues to rise, Ashwagandha stands at the intersection of traditional knowledge, scientific validation, and economic opportunity. It is therefore essential that policy discussions around this herb remain evidence-based, balanced, and supportive of India’s Ayurvedic and nutraceutical industries.
Ashwagandha has long been used in classical Ayurvedic formulations and continues to attract attention for its adaptogenic, anti-inflammatory, and restorative properties. While modern scientific research is still evolving, a growing body of literature supports the therapeutic potential of both roots and leaves. At the same time, the herb has become commercially important, not only in India but also across international markets where Ashwagandha-based products are now widely consumed based on science. This makes it more than a medicinal herb; it is also a strategic agricultural, industrial, and export commodity for India.
Recent regulatory actions, however, have created uncertainty around the use of Ashwagandha leaves in food, health supplements, and AYUSH products. The concern appears to have been driven by safety discussions in some international markets and by the perceived need to ensure consumer protection. Yet industry stakeholders have consistently argued that the leaf has a legitimate place in the Ashwagandha value chain. They point to traditional usage, scientific studies, and pharmacovigilance data that do not establish an adverse safety signal specific to leaf use. In their view, a blanket restriction risks undermining legitimate products, disrupting trade, and harming farmers and manufacturers without adequately distinguishing between different product types and quality standards.
One of the most important points in this debate is the need to separate the safety profile of the plant itself from the safety profile of specific branded extracts or formulations. Ashwagandha is not a single uniform product. A root powder, a leaf extract, a multi-herb supplement, and a branded concentrated extract may all differ significantly in composition, dosage, and biological effect. Therefore, if concerns arise around one proprietary extract, it is scientifically inappropriate to generalise those concerns to all Ashwagandha derivatives. This distinction matters for public policy because regulatory action should be proportionate, product-specific, and grounded in evidence.
The same principle applies to ingredient transparency and manufacturing standards. Any herbal product, whether from Ashwagandha or another botanically sourced ingredient, must be manufactured under clear quality controls, with accurate labeling and appropriate testing. But the existence of safety questions around one formulation should not be used to discredit an entire traditional herb, especially when that herb has long been part of Ayurveda and continues to be supported by modern research. India’s strength in traditional medicine lies precisely in its ability to combine heritage with scientific rigor rather than to pit one against the other.
For the AYUSH sector, Ashwagandha represents both a cultural legacy and a commercial opportunity. For farmers, it provides a potentially valuable crop with market demand. For manufacturers, it offers a widely recognised ingredient in an expanding wellness category. For exporters, it contributes to India’s positioning as a global supplier of trusted herbal products. Any policy that weakens confidence in Ashwagandha as a category may have downstream effects on livelihoods, investment, and India’s reputation in the natural health space.
It is also important to consider the broader consumer context. Around the world, consumers are increasingly seeking plant-based products for stress management, general vitality, and preventive wellness. Ashwagandha has become one of the most recognizable names in this category. If India supports responsible and transparent use of the herb, it can strengthen its leadership in the global nutraceutical market. This requires a regulatory approach that encourages compliance, labeling discipline, post-market surveillance, and scientific review, while avoiding unnecessary restrictions that may stifle innovation.
A more constructive path forward would be to differentiate between traditional use, validated formulations, and questionable claims. Manufacturers should be expected to substantiate product composition, dosage, and quality. Regulators should focus on misleading claims, non-compliance, and adulteration. At the same time, policymakers should ensure that traditional botanicals with established cultural and commercial significance are not penalized because of concerns tied to specific products or isolated reports. Such an approach would protect consumers without weakening the broader Ayurvedic and nutraceutical ecosystem.
Ashwagandha deserves to be treated as a serious herbal asset for India. Its future should be shaped by science, quality, and responsible regulation, not by fear or oversimplification. If there are safety concerns related to any particular branded extract, those concerns should be investigated directly and transparently. But they should not eclipse the broader value of Ashwagandha leaves, roots, and traditional formulations that have supported wellness for generations.
India has the opportunity to lead the world in evidence-based Ayurveda. Preserving Ashwagandha’s rightful place in AYUSH and nutraceuticals is part of that mission. The goal should not be to restrict a heritage botanical, but to regulate it wisely, communicate honestly, and strengthen trust across the value chain. In doing so, India can protect consumers, support farmers and manufacturers, and uphold the global reputation of Ayurveda.
Importantly, disregarding rigorous safety research on Ashwagandha leaves would erode confidence across the research and development ecosystem. In the short term, researchers and funders may pause ongoing studies and delay new projects while they reassess whether evidence will be respected. Over the medium term, that hesitation could translate into reduced private and public R&D investment, fewer clinical trials, and a slower pipeline of improved formulations and safety monitoring.
In the long term, sidelining validated scientific findings risks changing incentives: aspiring scientists and industry players may shift away from botanical research toward safer, better supported fields. That sequence raises a fundamental policy question, if regulatory authorities say R&D is a national priority but routinely ignore validated science, why should stakeholders continue to invest effort and capital? Science should guide proportionate regulation, not be sidelined in favor of blanket prohibitions; protecting evidence-based inquiry is essential to safeguard public health, sustain innovation, and support India’s herbal industry.
